РОЛЬ ХІРУРГІЧНОГО ЕТАПУ В ЛІКУВАННІ ХВОРИХ З ЛОКАЛЬНИМ РЕЦИДИВОМ РАКУ ЯЄЧНИКІВ

V V Boyko, K V Kharchenko, S O Savvi, O P Manzhura, O M Kliusov

Анотація


У процесі виконання даного дослідження вивчені комбіновані та розширені хірургічні втручання на ректосигмоїдному відділі товстої кишки, виконані в якості компонента вторинної циторедукціі при рецидиві раку яєчників. Видалення відділу товстої кишки, ураженої рецидивною пухлиною, проводилося відповідно до принципів онкохірургії для первинних злоякісних новоутворень цієї локалізації. Медіана загальної та безрецидивної виживаності після вторинної хірургічної циторедукції склала 43 і 29 місяців, відповідно. На показники виживаності впливали глибина інвазії рецидиву раку яєчників у стінку товстої кишки і наявність вторинного ураження лімфатичних вузлів.

Ключові слова


рецидив раку яєчника; вторинна циторедукція; хірургічне лікування; пряма кишка; сигмоподібна кишка

Повний текст:

PDF

Посилання


Bickell NA, Egorova N, Prasad-Hayes M, Franco R, Howell EA, Wisnivesky J, et al. Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer. Am J Clin Oncol. 2016; DOI:10.1097/COC.0000000000000310.

Sahdev A, Hughes JH, Barwick T. Computed tomography features of recurrent ovarian carcinoma according to time lapse. Acta Radiol. 2007;48:1038-44.

Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 2001;82(3):435-41.

Hertel H, Diebolder H, Herrmann J, Köhler C, Kühne-Heid R, Possover M,et al. Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol. 2001;83(3):481-4.

Hoffman MS, Griffin D, Tebes S, Cardosi RJ, Martino MA, Fiorica JV, et al. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol. 2005;193(2):582-6.

Hoffman MS, Zervose E. Colon resection for ovarian cancer: intraoperative decisions. Gynecol Oncol. 2008;111(2 Suppl):S56-65.

Kim HS, Kim EN, Jeong SY, Chung HH, Kim YB, Kim JW, et al. Comparison of the efficacy of low anterior resection with primary anastomosis and Hartmann's procedure in advanced primary or recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):194-8.

Barber HRK, Brunschwig A. Pelvic exenteration for called vance and recurrent ovarian cancer. Surgery. 1965;58:935-7.

Hudson CN, Chir M. Surgical treatment of ovarian cancer. Gynecol. Oncol. 1973;1:370-8.

Hudson CN. A radical operation for fixed ovarian tumours. J Obstet Gynaecol Br Commonw. 1968;75(11):1155-60.

Barnes W, Johnson J, Waggoner S, Barter J, Potkul R, Delgado G. Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors. Gynecol Oncol. 1991;42(2):151-5.

Berek JS, Hacker NF, Lagasse LD. Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Obstet Gynecol. 1984;64(5):715-20.

Bridges JE, Leung Y, Hammond IG, McCartney AJ. En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: the KEMH experience. Int J Gynecol Cancer. 1993;3(4):199-202.

Clayton RD, Obemair A, Hammond IG. The western Australian experience of the use of enbloc resection of ovarian cancer with concomit an trectosig moidcolectomy. Gynecol. Oncol. 2002;84:53-7.

Houvenaeghel G, Gutowski M, Buttarelli M, Cuisenier J, Narducci F, Dalle C, et al. Modified posterior pelvic exenteration for ovarian cancer. Int J Gynecol Cancer. 2009;19(5):968-73.

Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC, et al. A. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001;83(1):115-20.

Sainz de la Cuesta R, Goodman A, Halverson SS. En bloc pelvic peritoneal resection of the intraperitoneal pelvic viscera in patients with advanced epithelial ovarian cancer. Cancer J Sci Am. 1996;2(3):152-7.

Sonnendecker EW, Beale PG. Rectosigmoid resection without colostomy during primary cytoreductive surgery for ovarian carcinoma. Int Surg. 1989;74(1):10-2.

Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol. 1991;41(3):239-44.

Tamussino KF, Lim PC, Webb MJ, Lee RA, Lesnick TG. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol. 2001;80(1):79-84.

Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103(2):667-72.

Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112(1):265-74.

Cai HB, Zhou YF, Chen HZ, Hou HY. The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clin. Oncol. (R. Coll. Radiol.). 2007;19(10):757-62.

Estes JM, Leath CA, Straughn JM. Bowel resection at the time of prima ryde bulking for epithelial ovarian carcinoma: out comesin patients treated with platinum and taxane-based chemotherapy. J. Am. Coll. Surg. 2006;203:527-32.

Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107(3):495-9.

Tebes SJ, Cardosi R, Hoffman MS. Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol. 2006;195(2):585-9.

Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007;14(12):3552-7.

Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009;114(2):173-7.

Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933-9.

Gallotta V, Fanfani F, Vizzielli G, Panico G, Rossitto C, Gagliardi ML, et al. Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome. Eur J Surg Oncol. 2011;37(12):1085-92.

Bidzinski M, Derlatka P, Kubik P, Ziolkowska-Seta I, Dańska-Bidzinska A, Gmyrek L, et al. The evaluation of intra- and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III-IV ovarian cancer. Int J Gynecol Cancer. 2007;17(5):993-7.

Di Giorgio A, Cardi M, Biacchi D, Sibio S, Accarpio F, Ciardi A, et al. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J Surg Oncol. 2013;11:64.

Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukazawa EM, Faloppa CC, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011 Sep 1;104(3):250-4.

Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012 Feb;38(2):170-5.

Lax SF, Petru E, Holzer E, Pertl AM, Ralph G, Greenspan DL, et al. Mesenteric and mesocolic lymph node metastases from ovarian carcinoma: a clinicopathological analysis. Int J Gynecol Cancer. 1998;8:119-23.

Park JY, Seo SS, Kang S, Lee KB, Li SY, Cho HS, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol. Oncol. 2006;103(3):977-84.

O'Hanlan KA, Kargas S, Schreiber M, Burrs D, Mallipeddi P, Longacre T, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995 Nov;59(2):200-6.

Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000 Jan 15;88(2):389-97.

Höckel M. Laterally extended endopelvic resection (LEER)-principles and practice. Gynecol Oncol. 2008;111(2 Suppl):S13-7.

Hockel M. Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol Oncol. 2003 Nov;91(2):369-77.

Kato K, Tate S, Nishikimi K, Tate S, Kiyokawa T, Shozu M. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration. World J Surg Oncol. 2015;13:230.

Kato K, Tate S, Nishikimi K, Shozu M. Bladder functionafter modified posterior exenteration for primary gynecological cancer. Gynecologic Oncology. 2013;129(1):229-33.


Пристатейна бібліографія ГОСТ


1. Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer / N.A. Bickell, N. Egorova, M. Prasad-Hayes [et al.] // Am. J. Clin. Oncol. – 2016. – DOI:10.1097/COC.0000000000000310.

2. Computed tomography features of recurrent ovarian carcinoma according totimet orelapse / A. Sahdev, J.H. Hughes, T. Barwick [et al.] // Acta Radiol. – 2007. – V. 48. – P. 1038-1044.

3. Eisenkop S.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? / S.M. Eisenkop, N.M. Spirtos // Gynecol Oncol. – 2001. – V. 82. – P. 435-441.

4. Isthedecision for colorectal resection justified byhistopathologi cfindings: a prospective study of 100 patients with advancedo varian cancer / H. Hertel, H. Diebolder, J. Herrmann [et al.] // Gynecol Oncol. – 2001. – V. 83. – P. 481-484.

5. Sitesof bowel resectedto achieve optimal ovarian cancer cyto reduction: implications regarding surgical management / M.S. Hoffman, D. Griffin, S. Tebes [et al.] // Am. J. Obstet Gynecol. – 2005. – V. 193. – P. 582-588.

6. Hoffman M.S. Colon resection for ovarian cancer: intraoperative decisions / M.S. Hoffman, E. Zervose // Gynecol. Oncol. – 2006. – V. 111. – P. 56-65.

7. Comparison of the efficacyo flowanterior resection with prima ryanas tomosisand Hartmann’s procedurein advanced primary orrecurrent epithelial ovarian cancer / H.S. Kim, E.N. Kim, S.Y. Jeong [et al.] // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2011. – V. 156(2). – P. 194-198.

8. Barber H.R.K. Pelvic exenteration forlo callyad van cedand recurrent ovarian cancer / H.R.K. Barber, A. Brunschwig // Surgery. – 1965. – V. 58. – P. 935-937.

9. Hudson C.N. Surgical treatment of ovarian cancer / C.N. Hudson, M. Chir // Gynecol. Oncol. – 1973. – V. 1. – P. 370-378.

10. Hudson C.N. A radical operation for fix ed ovarian tumors / C.N. Hudson // J. Obstet. Gynaecol. Br. Commonw. – 1968. – V. 75. – P. 1155-1160.

11. Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors / W. Barnes, J. Johnson, S. Waggoner [et al.] // Gynecol. Oncol. – 1991. – V. 42. – P. 151-155.

12. Berek J.S. Rectosigmoidcolectomy andre anastomosis to facilitate resection of prima ryand recurrent gynecologic cancer / J.S. Berek, N.F. Hacker, L.D. Lagasse // Obstet. Gynecol. – 1984. – V. 64. – P. 715-720.

13. Enbloc resection of epithelial ovarian tumors with con comitant rectosigmoidcolectomy: the KEMH experience / J.E. Bridges, Y. Leung, I.G. Hammond [et al.] // Int. J. Gynecol. Cancer. – 1993. – V. 3. – P. 199-202.

14. The western Australian experience of the use of enbloc resection of ovarian cancer with concomit an trectosig moidcolectomy / R.D. Clayton, A. Obemair, I.G. Hammond [et al.] // Gynecol. Oncol. – 2002. – V. 84. – P. 53-57.

15. Eisenkop S.M. Modified posterior exenteration for ovarian cancer / S.M. Eisenkop, R.H. Nalick, N.N. Teng // Obstet. Gynecol. – 1991. – V. 78. – P. 879-885.

16. Safety and efficacy of low anterior enbloc resection aspart of cytoreductive surgery for patients with ovarian cancer / A. Obermair, S. Hagenauer, D. Tamandl [et al.] // Gynecol. Oncol. – 2001. – V. 83. – P. 115-120.

17. Enbloc pelvic peritoneal resection of the intraperitoneal pelvic viscerain patients with advanced epithelial ovarian cancer / R. Sainzdela Cuesta, A.Goodman, S.S. Halverson [et al.] // Cancer J. Sci Am. – 1996. – V. 2. – P. 152-157.

18. Sonnendecker E.W.W. Rectosigmoid resection with out colostomy during primary cyto reductive surgery for ovarian carcinoma / E.W.W. Sonnendecker, P.G. Beale // Int. Surg. – 1989. – V. 74. – P. 10-12.

19. The role of partial sigmoidcolectomy for debulk ing epithelial ovarian carcinoma / J.T. Soper, G. Couchman, A. Berchuk [et al.] // Gynecol. Oncol. – 1991. – V. 41. – P. 239-244.

20. Gastrointestinal surgery in patients with ovarian cancer / K.F. Tamussino, P.C. Lim, M.J. Webb [et al.] // Gynecol. Oncol. – 2001. – V. 80. – P. 79-84.

21. Risk factors for anastomoticleak after rectosigmoid resection for ovarian cancer / D.L. Richardson, A. Mariani, W.A. Cliby // Gynecol. Oncol. – 2006. – V. 103. – P. 667-672.

22. Bristow R.E. Cyto reductive surgery for recurrent ovarian cancer: a meta-analysis / R.E. Bristow, I. Puri, D.S. Chi // Gynecol. Oncol. – 2009. – V. 112. – P. 265-274.

23. The role of bowel surgery with cyto reduction for epithelial ovarian cancer / H.B. Cai, Y.F. Zhou, H.Z. Chen [et al.] // Clin. Oncol (R. Coll. Radiol). – 2007. – V. 19(10). – P. 757-762.

24. Bowel resection at the time of prima ryde bulking for epithelial ovarian carcinoma: out comesin patients treated with platinum and taxane-based chemotherapy / J.M. Estes, C.A. Leath, J.M. Straughn [et al.] // J. Am. Coll. Surg. – 2006. – V. 203. – P. 527-532.

25. Salani R. Survival impact of multiplebowel resections in patients und ergoing primary cyto reductive surgery for advanced ovarian cancer: a case-controlstudy / R. Salani, M.L. Zahurak, A. Santillan [et al.] // Gynecol. Oncol. – 2007. – V. 107. – P. 495-499.

26. Tebes S.J. Colorectal resection in patients with ovarian and primary peritoneal carcinoma / S.J. Tebes, R. Cardosi, M.S. Hoffman // Am. J. Obstet. Gynecol. – 2006. – V. 195. – P. 585-589.

27. Surgical management of mesenteric lymphnode metastasis in patients under going rectosigmoid colectomy for locally advanced ovarian carcinoma / R. Salani, T. Diaz-Montes, R.L. Giuntoli [et al.] // Ann. Surg. Oncol. – 2007. – V. 14. – P. 3552-3557.

28. Secondary cyto reductive surgery in cluding rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical out come / R.E. Bristow, M. Peiretti, M.Gerardi [et al.] // Gynecol. Oncol. – 2009. – V. 114(2). – P. 173-177.

29. Chi D.S. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent platinum-sensitive epithelial ovarian carcinoma / D.S. Chi, K. McCaughty, J.P. Diaz [et al.] // Cancer. – 2006. – V. 106. – P. 1933-1939.

30. Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome / V. Gallotta, F. Fanfani, G.Vizzielli [et al.] // Eur. J. Surg. Oncol. – 2011. – V. 37. – P. 1085-1092.

31. The evaluation of intra- and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III-IV ovarian cancer / M. Bidzinski, P. Derlatka, P. Kubik [et al.] // Int. J. Gynecol. Cancer. – 2007. – V. 17. – P. 993-997.

32. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases / A. Di Giorgio, M. Cardi, D. Biacchi [et al.] // World J. Surg. Oncol. – 2013. – V. 11. – P. 64.

33. Surgical implications of mesenteric lymphnodemetastasis from ad vanced ovarian cancer after bowel resection / G. Baiocchi, L.A. Cestari, M.P. Macedo [et al.] // J. Surg. Oncol. – 2011. – V. 104. – P. 250-254.

34. Prognostic factors for and prognostic value of mesenteric lymphnode in volvementin advanced-stage ovarian cancer / S. Gouy, J. Goetgheluck, C. Uzan [et al.] // Eur. J. Surg. Oncol. – 2012. – V. 38. – P. 170-175.

35. Mesenteric and mesocolic lymphnode metastases from ovarian carcinoma: a clinicopathological analysis / S.F. Lax, E. Petru, E. Holzer [et al.] // Int. J. Gynecol. Cancer. – 1998. – V. 8. – P. 119-123.

36. The benefits of low anterior enbloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients out weigh morbidity concerns / J.Y. Park, S.S. Seo, S. Kang [et al.] // Gynecol. Oncol. – 2006. – V. 103. – P. 977-984.

37. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection / K.A. O'Hanlan, S. Kargas, M. Schreiber [et al.] // Gynecol. Oncol. – 1995. – V. 59. – P. 200-206.

38. Primary cyto reductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma / C. Scarabelli, A. Gallo, S. Franceschi [et al.] // Cancer. – 2000. – V. 88. – P. 389-397.

39. Höckel M. Laterally extended endopelvic resection (LEER) – principles and practice / M.Höckel // Gynecol. Oncol. – 2008. – V. 111. – P. 13-17.

40. Hockel M. Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic sidewall / M. Hockel // Gynecol Oncol. – 2003. – V. 91. – P. 369-377.

41. Histopathologic tumors preading in primary ovarian cancer with modified posterior exenteration / K. Kato, K. Nishikimi, S. Tate [et al.] // World J. Surg. Oncol. – 2015. – V. 13. – P. 230.

42. Bladder functionafter modified posterior exenteration for primary gynecological cancer / K. Kato, S. Tate, K. Nishikimi [et al.] // Gynecol. Oncol. – 2013. – V. 129. – P. 229-233.





DOI: https://doi.org/10.24061/1727-0847.16.1.2017.36

Посилання

  • Поки немає зовнішніх посилань.


Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

ISSN 1727-0847 (Print)
ISSN 1993-5897 (On-line)